Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lotus-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:20568:1" rel="noopener">Lotus Pharmaceutical (1795 TT)</a> achieved 16% revenue growth to NT$17B in 2023, while net profit increased 36% to NT$4B. Growth was mainly driven by the strong performance of Asian business.</li>
<li>For the first two months of 2024, the company reported revenue of NT$3B, representing 1% YoY decline. While exports grew, Asia business remained flat. </li>
<li>1Q24 should be flat or slightly negative for the company, while growth is expected to pick up from the later half of the year.</li>
</ul>



Lotus Pharmaceutical (1795 TT) achieved 16% revenue growth to NT$17B in 2023, while net profit increased 36% to NT$4B. Growth was mainly driven by the strong performance of Asian business.
For the first two months of 2024, the company reported revenue of NT$3B, representing 1% YoY decline. While exports grew, Asia business remained flat. 
1Q24 should be flat or slightly negative for the company, while growth is expected to pick up from the later half of the year.


Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

Taiwan

TTY Biopharm Co., Ltd. manufactures and markets various kinds of medicines. The company's products encompass a variety of therapeutic segments, including cardiology, gastroenterology, orthopedics and cancer.

Tty Biopharm (4105 TT)

Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

Lotus achieved 16% and 36%, YoY, revenue and profit growth, respectively, in 2023. The company is facing slight revenue decline in early 2024,...

Tina Banerjee

Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

​Lotus achieved 16% and 36%, YoY, revenue and profit growth, respectively, in 2023. The company is facing slight revenue decline in early 2024,...

Tina Banerjee

Lotus achieved 16% and 36%, YoY, revenue and profit growth, respectively, in 2023. The company is facing slight revenue decline in early 2024,...